Payment overview · 2025
General Payments
$359.15
19 reported records · 10 companies
Healthcare provider profile · identity verified
Mary Prem, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MUNSTER, IN · NPI 1912918301
Verified facts
What the public records show
CMS Open Payments records show Mary Prem, MD received $359.15 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.94 | 15.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.81 | 13.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.27 | 13.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.55 | 12.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.47 | 9.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.85 | 9.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.44 | 8.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.13 | 8.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.14 | 4.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.55 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $359.15 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.94 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.55 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.44 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.40 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 734 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 135 |
| Alprazolam | Alprazolam | 401 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 275 | 74 |
| Metformin Hcl | Metformin Hcl | 261 | 78 |
| Losartan Potassium | Losartan Potassium | 257 | 70 |
| Lisinopril | Lisinopril | 244 | 75 |
| Gabapentin | Gabapentin | 226 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 56 |
| Simvastatin | Simvastatin | 211 | 58 |
| Alendronate Sodium | Alendronate Sodium | 210 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 166 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 47 |
| Sertraline Hcl | Sertraline Hcl | 153 | 34 |
| Omeprazole | Omeprazole | 148 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 47 |
| Furosemide | Furosemide | 132 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 41 |
| Ozempic | Semaglutide | 127 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 26 |
| Glipizide | Glipizide | 118 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 26 |
| Carvedilol | Carvedilol | 97 | 31 |
| Allopurinol | Allopurinol | 90 | 23 |
| Eliquis | Apixaban | 78 | 16 |
| Montelukast Sodium | Montelukast Sodium | 78 | 26 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Glimepiride | Glimepiride | 71 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 66 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 20 |
| Spironolactone | Spironolactone | 54 | 15 |
| Ezetimibe | Ezetimibe | 52 | 16 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 50 | 11 |
| Meloxicam | Meloxicam | 49 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 17 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 42 | 16 |
| Trulicity | Dulaglutide | 42 | 12 |
| Xarelto | Rivaroxaban | 42 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 32 |
| Metformin Hcl Er | Metformin Hcl | 39 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Atenolol | Atenolol | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 31 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | 12 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $359.15 · 19 records | Amgen Inc. | CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error